Imperial College London
Alternate

ProfessorMartinCowie

Faculty of Medicine, National Heart & Lung Institute

Visiting Professor
 
 
 
//

Contact

 

+44 (0)20 7351 8856m.cowie

 
 
//

Assistant

 

Mr Jacob Chapman +44 (0)20 7351 8856

 
//

Location

 

Chelsea WingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Cowie:2020:cvr/cvz278,
author = {Cowie, MR and Lamy, A and Levy, P and Mealing, S and Millier, A and Mernagh, P and Cristeau, O and Bowrin, K and Briere, J-B},
doi = {cvr/cvz278},
journal = {Cardiovascular Research},
pages = {1918--1924},
title = {Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease},
url = {http://dx.doi.org/10.1093/cvr/cvz278},
volume = {116},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - AIMS: In the COMPASS trial, rivaroxaban 2.5 mg twice daily (bid) plus acetylsalicylic acid (ASA) 100 mg once daily (od) performed better than ASA 100 mg od alone in reducing the rate of cardiovascular disease, stroke, or myocardial infarction (MI) in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). A Markov model was developed to assess the cost-effectiveness of rivaroxaban plus ASA vs. ASA alone over a lifetime horizon, from the UK National Health System perspective. METHODS AND RESULTS: The base case analysis assumed that patients entered the model in the event-free health state, with the possibility to experience ≤2 events, transitioning every three-month cycle, through acute and post-acute health states of MI, ischaemic stroke (IS), or intracranial haemorrhage (ICH), and death. Costs, quality-adjusted life-years (QALYs), life years-all discounted at 3.5%-and incremental cost-effectiveness ratios (ICERs) were calculated. Deterministic and probabilistic sensitivity analyses were conducted, as well as scenario analyses. In the model, patients on rivaroxaban plus ASA lived for an average of 14.0 years with no IS/MI/ICH, and gained 9.7 QALYs at a cost of £13 947, while those receiving ASA alone lived for an average of 12.7 years and gained 9.3 QALYs at a cost of £8126. The ICER was £16 360 per QALY. This treatment was cost-effective in 98% of 5000 iterations at a willingness-to-pay threshold of £30 000 per QALY. CONCLUSION: This Markov model suggests that rivaroxaban 2.5 mg bid plus ASA is a cost-effective alternative to ASA alone in patients with chronic CAD or PAD.
AU  - Cowie,MR
AU  - Lamy,A
AU  - Levy,P
AU  - Mealing,S
AU  - Millier,A
AU  - Mernagh,P
AU  - Cristeau,O
AU  - Bowrin,K
AU  - Briere,J-B
DO  - cvr/cvz278
EP  - 1924
PY  - 2020///
SN  - 0008-6363
SP  - 1918
TI  - Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease
T2  - Cardiovascular Research
UR  - http://dx.doi.org/10.1093/cvr/cvz278
UR  - https://www.ncbi.nlm.nih.gov/pubmed/31807773
UR  - http://hdl.handle.net/10044/1/78666
VL  - 116
ER  -
Download